Hospice Nurse with 3 Million Social Media Followers Partners with Medical Device Company

“Hospice Nurse Julie” and Hospi Corporation–the maker of the Macy Catheter–are pleased to announce their partnership.

Julie McFadden, RN is one of the leading voices working to demystify hospice and end of life care on social media. She is known as “Hospice Nurse Julie” to her sizable audience of over 3 million collective followers across Instagram, TikTok, Facebook, and YouTube.

McFadden and medical device company Hospi Corporation share the mission to reduce suffering at end-of-life. Hospi introduced the first innovation to hospice bedside care in decades when it launched the Macy Catheter. The device provides rectal access for medication and fluid administration so patients can immediately continue receiving medications when they can’t take them by mouth. Over 100,000 patients have benefited from the rapid symptom management enabled by the Macy Catheter.

Hospice Nurse Julie and Hospi work together to spread the word about how the Macy Catheter improves quality of life for hospice patients and their caregivers.

When asked about why Hospi and McFadden chose to partner with each other, Hospi CEO Igal Ladabaum said, “It was a revelation to me that people are turning to trusted online personalities even for the most intimate of healthcare topics, but after coming across Hospice Nurse Julie I understood why and I immediately knew that we needed to work together. With access to good information, patients and families can better advocate for themselves and their loved ones.”

McFadden shared, “When I first learned about the Macy Catheter, it was a no-brainer. My first thought was– Why didn’t I think of this? It’s an easy decision to partner with a product and company so aligned with my mission.”

Ladabaum further elaborated, “The Macy Catheter is basically a soft little tube that is placed in the rectum. Many people initially recoil at the thought of the rectal route. We needed the right partner in order to communicate that the Macy Catheter actually makes the rectal route comfortable and dignified.”

Julie McFadden–known as “Hospice Nurse Julie“–is a hospice nurse and social media influencer known for her compassionate and educational content on hospice care. Her social media presence has made her a trusted voice in the hospice community. She uses her platform to share valuable insights, personal stories, and educational content. Julie is also the author of “Nothing to Fear,” which offers a deeper look into her professional insights and her personal experiences in the field.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version